MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.540
-0.080
-2.21%
Opening 11:58 09/23 EDT
OPEN
3.650
PREV CLOSE
3.620
HIGH
3.650
LOW
3.440
VOLUME
21.80K
TURNOVER
--
52 WEEK HIGH
31.35
52 WEEK LOW
1.871
MARKET CAP
35.74M
P/E (TTM)
-1.1196
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACER and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACER News

  • Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm
  • GlobeNewswire.09/12 01:00
  • Acer Therapeutics: Undervalued With A Free Call Option On EDSIVO
  • Seeking Alpha - Article.09/05 12:51
  • Shareholder Alert: Robbins Arroyo LLP Reminds Investors Acer Therapeutics Inc. (ACER) Sued for Misleading Shareholders
  • Business Wire.08/30 18:02
  • FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019
  • ACCESSWIRE.08/30 15:04

More

Industry

Biotechnology & Medical Research
-0.31%
Pharmaceuticals & Medical Research
-0.19%

Hot Stocks

Name
Price
%Change

About ACER

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
More

Webull offers Acer Therapeutics Inc (ACER) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.